Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
On 29 April 2025, ADI Regional Director for the Americas, Diego Aguilar attended the Symposium on Brain Health Promotion: Towards a National Dementia Plan in Buenos Aires, Argentina, during which key political figures, international experts, civil society leaders, and advocates joined the call for the urgent approval of Argentina’s first National Dementia Plan.
In March 2025, ADI was involved in a range of engagements across the Latin American region, from high level symposiums in Curaçao and Mexico, to providing strategic input on draft bills in Argentina and the international bloc of Latin American countries MERCOSUR.
This month, ADI CEO Paola Barbarino and ADI Director of Research and Publications, Wendy Weidner, travelled to the East Coast of the United States to meet with leading researchers, universities, and industry innovators to discuss recent advancements in the research and innovation sphere of dementia care.
In February, ADI representatives took part in two important events in the Americas showcasing the great progress currently being made in the region.ADI Board Member Rosa Farrés attended a workshop in Peru on Advancing Brain Health, hosted by the Global Brain Health Institute at the beginning of the month. Then, ADI Regional Director for the Americas, Diego Aguilar, visited Chile to attend the Alzheimer’s Association International Conference (AAIC) Neuroscience Next conference, building on Chile’s recent efforts on the updating of their National Dementia Plan strategy.